ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS178

7.10. Combined Blockade Of Src Kinase And EpidermalGrowth Factor Receptor With Gemcitabine OvercomesSTAT3-Mediated ResistanceOf Inhibition Of PancreaticTumor Growth. E. H. Liu, N. S. Nagaraj, M. K. Washington,N. B. Merchant; Vanderbilt University Medical Center,Nashville, TN

7.11. Differential Regulation Of Tumor Suppressor PDCD4Expression By Rapamycin. F. Adkins,1 W. Kim,1 A.Akcakanat,1 G. Singh,1 M. Hung,2 F. Meric-Bernstam1;1Department of Surgical Oncology, the University of TexasMD Anderson Cancer Center, Houston, TX; 2Department ofMolecular and Cellular Oncology, the University of Texas MDAnderson Cancer Center, Houston, TX

7.12. Liposome-Encapsulated Curcumin Suppresses Neuro-blastoma Growth Through Nuclear Factor-kB Path-way Inhibition. W. S. Orr,1,2 J. W. Denbo,1,2 C. Y. Ng,1

A. L. Myers,1,2 C. L. Morton,1 K. R. Saab,1 L. M. Pfeffer,3

A. M. Davidoff1,2; 1St Jude Children’s Research Hospital,Department of Surgery, Memphis, TN; 2University ofTennessee Health Science Center, Department of Surgery,Memphis, TN; 3University of Tennessee Health ScienceCenter, Department of Pathology, Memphis, TN

7.13. Increased PIP3 Levels Reflect Aberrant PI3 Kinase Ac-tivity AndMetastatic Capability InAnOrthotopicModelof Colorectal Cancer. A. Rajput,1 M. Ongchin,2 G. Wan,1 E.Sharratt,3 B. Wilson4; 1Division of Surgical Oncology,Albuquerque, NM; 2Department of Surgery, Buffalo, NY;3Department of Pathology, Morgantown, WV; 4Department ofPathology, Albuquerque, NM

7.14. The Angiotensin II Type 2 Receptor Blocker, PD 123319,Inhibits Fatty Acid Synthase Production Through Acti-vation Of AMP-Activated Protein Kinase In PancreaticCancer Cells. A. McGhee, Q. Gong, G. Chipitsyna, M.Sivarajah, C. J. Yeo, H. Arafat; Thomas Jefferson University,Philadelphia, PA

7.15. Raf Kinase Inhibitory Protein (RKIP) Mediates EtOH-induced Sensitization of Secretagogue Signaling in Pan-creatic Acinar Cells. S. O. Kim, K. L. Ives, J. Park, X. Wang,C. D. Djukom, C. Chao, M. R. Hellmich; University of TexasMedical Branch, Galveston, TX

7.16. Integrin-Linked Kinase (ILK) Co-Localizes with PTENinRegulating PI3K/Akt Activity inNeuroblastomaCells.C. Taylor, J. Qiao, E. Josifi, D. H. Chung; Vanderbilt UniversityMedical Center, Nashville, TN

7.17. ExposureToBileAcidsAlters IntracellularExpressionOfMnSODInBarrett’sEsophagus.R.Farmer, Y. Li, X.Kang,N.Harper, R. C. Martin; University of Louisville Depatment ofSurgery - Division of Surgical Oncology, Louisville, Ky

7.18. Lysophosphatidic Acid Biosynthesis ReprogrammingAndBiomarkerDiscovery InHepatocellularCarcinoma.S. Samuel, J. Wu, N. Skill, M. Maluccio; Indiana University,Indianapolis, IN

7.19. Epigenetic Silencing of EzH2 By RNA Interference As APotential Therapy For Pancreatic Adenocarcinoma.R. B. Batchu,1,2 A. M. Qazi,1,2,4 A. Y. Semaan,2,3 S. M.Seward,2,3 S. Chamala,1,2 V. B. Dhulipala,1,2 C. David,1 C. S.Bryant,3 S. Kumar,3 C. Steffes,1,2,4 P. Philip,1,4 D. Bouwman,1,4

D. W. Weaver1,2,4; 1Wayne State University, Detroit, MI; 2JohnD Dingell VA Medical Center, Detroit, MI; 3Wayne StateUniversity, Detroit, MI; 4Karmanos Cancer Institute, Detroit,MI

7.20. Silencing of CDC42 Inhibits Neuroblastoma Cell Prolif-eration and Transformation via Downregulation ofTWIST and AKT2. S. Lee, J. Qiao, J. Zhang, D. H. Chung;Vanderbilt University Medical Center, Nashville, TN

ONCOLOGY 3: WOMEN’S HEALTH: BREAST &REPRODUCTIVE SYSTEM

8.1. Malignancies Associated With Germline And SomaticNF1 Gene Mutations. S. Patil1 R. Chamberlain1,2,3;1Department of Surgery, Saint Barnabas Medical Center,Livingston, NJ; 2Saint Georges University School of Medicine,Grenada, Grenada; 3Department of Surgery, University ofMedicine and Dentistry of New Jersey, Newark, NJ

8.2. Undocumented Status Does Not Decrease Survival inMedically Underserved Breast Cancer Patients. E.Castro-Echeverry, L. S. Kao, C. J. Wray; University of TexasMedical School At Houston, Houston, TX

8.3. Current Use of Perioperative Antibiotics Among BreastCancer Patients. C. Dodgion,1 A. Karcz,3 W. Jiang,1 S.Lipsitz,1 C. Greenberg1,2; 1Center for Surgery and PublicHealth - Brigham and Women’s Hospital, Boston, MA; 2Centerfor Outcomes & Policy Research, Dana Farber CancerInsititute, Boston, MA; 3Institute for Health Metrics,Burlington, MA

8.4. Differences In Approach To Breast Conservation Opera-tions: Fellowship Trained Vs Nonfellowship TrainedBreast Surgeons. S. L. Blair,1 V. Roma,2 V. Malcarne2;1University of California San Diego, Moores’ Cancer Center, LaJolla, CA; 2San Diego State University, Department ofPsychology, San Diego, CA

8.5. Factors Affecting Survival Following First LocoregionalRecurrence After Surgically Managed Breast Cancer.C. L. Crutcher A. B. Chagpar; University of Louisville,Louisville, KY

8.6. Outcomes After Tumescence Technique Vs. Electrocatu-ery Mastectomy. A. M. Abbott, B. T. Miller, T. M. Tuttle;University of Minnesota, Minneapolis, MN

8.7. Impact Of a Free Access Multidisciplinary Program OnReducingBreast CancerDisparities By Insurance Status.E. C. Feliberti, S. C. Azoury, R. C. Britt, J. N. Collins, R. R. Perry;Eastern Virginia Medical School, Norfolk, VA